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ABSTRACT
Recent years have brought major strides to our understanding of prognostic pathobiologic factors in patients
with chronic lymphocytic leukemia. This has allowed identification of high-risk patients who may benefit from
more aggressive therapies, including hematopoietic cell transplantation. High-dose chemotherapy followed by
autologous hematopoietic cell transplantation is feasible, and results in encouraging responses, including
molecular responses, with low transplant-associated mortality. However, it has failed to show a plateau effect
on survival curves. On the other hand, there is convincing evidence that immunologically mediated graft-
versus-leukemia effect of donor T cells are responsible for lowering the incidence of relapse and allowing
possible “cure” in allograft recipients, albeit at the expense of high treatment-associated mortality using
conventional myeloablation. Reducing the intensity of conditioning regimens has translated into lesser toxicity
with reasonable preservation of its curative potential. Autologous or allogeneic hematopoietic cell transplan-
tation in high-risk chronic lymphocytic leukemia remain promising and evolving treatment options. Treatment
of CLL should consider stratification according to modern prognostic markers.
© 2007 American Society for Blood and Marrow Transplantation
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B cell chronic lymphocytic leukemia (B-CLL) is
he most common leukemia diagnosed in the Western
emisphere [1]. It is a complex disease characterized
y a variable clinical course and a median life expect-
ncy of 8 years [2,3]. In most cases, the disease exhibits
n indolent course requiring no immediate treatment,
ut others succumb rapidly even with aggressive ther-
py [2,3]. The prognosis of CLL is poor when adverse
rognostic factors such as 17p- and 11q-chromosomal
berrations, unmutated status of the variable region of
he immunoglobulin heavy chain gene (IgVH ), and
ncreased expression of surface CD38 and zeta-asso-
iated protein 70 (ZAP-70) are present [4-8]. CD38
nd ZAP-70 are independent prognostic markers that
trongly correlate with IgVH mutation [9,10], and
evels of expression of CD38 may vary during the
ourse of the disease [7]. mFludarabine has emerged as the therapy of choice
or CLL, but without evidence of a curative potential,
r survival advantage over traditional therapy with
hlorambucil [11]. The addition of cyclophosphamide
r the anti-CD20 monoclonal antibody (mAb) ritux-
mab to ﬂudarabine has improved the response rates
hen compared with chlorambucil or ﬂudarabine
lone. The combination of ﬂudarabine, cyclophosph-
mide, and rituximab appears even more potent in
ingle-arm studies [12,13]. Despite signiﬁcant
rogress in our understanding of the disease biology,
olecular ﬁngerprinting, and development of novel
harmacologic therapies, CLL remains incurable with
tandard treatments [14,15].
The availability of new prognostic factors and
ore effective drugs are challenging the “watchful
aiting” approach that has characterized the treat-
ent of CLL for the last decades. Transplantation of
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M. A. Kharfan-Dabaja et al.374utologous or allogeneic hematopoeitic cells provides
therapeutic option for CLL. Encouraging clinical
emission (CR) and molecular remissions (MRs) have
een reported following high-dose chemotherapy
HDCT) and autologous hematopoietic cell trans-
lantation (auto-HCT) in patients with poor prognos-
ic features [16,17]. However, auto-HCT has failed to
emonstrate a plateau in overall survival (OS) curves in
LL patients (Figure 1). On the other hand, alloge-
eic HCT (allo-HCT) does not rely solely on the
ytotoxic effect of HDCT, but also on the bona ﬁde
mmunologically mediated graft-versus-leukemia
GVL) effect of donor T cells, which are directed to
umor-associated antigens or to host-speciﬁc minor
istocompatibility antigens expressed by CLL cells.
urther improvement in patient’s outcomes by de-
reasing the toxicity of conditioning regimens and
reventing graft-versus-host disease (GVHD) is mak-
ng allo-HCT safer and more widely available to pa-
ients with CLL.
UTOLOGOUS HEMATOPOIETIC CELL
RANSPLANTATION
High dose chemotherapy followed by hematopoi-
tic cell rescue has been utilized for patients with
igh-risk CLL or for those who failed standard ther-
pies. To date, there have been no prospective ran-
omized studies comparing auto-HCT versus best
nduction chemotherapy for patients with high-risk
LL. Data in support of auto-HCT in the treatment
f CLL is based solely on prospective single-arm or
onrandomized comparative studies (autologous ver-
us allogeneic), and is therefore limited.
The feasibility of auto-HCT for CLL was dem-
igure 1. Probability of survival after transplants for CLL (from 199
f hematopoietic stem cell transplantation: part II—CIBMTR Sumnstrated by Rabinowe et al [18] in 1993. The inves- Higators evaluated the role of HCT in 20 patients with
oor-risk CLL. Patients received a uniform prepara-
ive regimen consisting of total-body irradiation and
yclophosphamide (TBI/CY) followed by rescue with
nti-B cell mAbs-purged autologous bone marrow
BM) (N  12) or T cell-depleted allogeneic BM
rom HLA-identical siblings (N  8). All patients
chieved hematologic reconstitution. Seventeen
89%) of 19 evaluable patients achieved CR, and 2
atients (1 allogeneic, 1 autologous) had persistent
M disease. Toxicity was similar among both treat-
ent modalities, and transplant-related mortality
TRM) was 10%. These results demonstrate that au-
o- and allo-HCT are feasible and relatively safe, sug-
esting a possible role for auto- or allografting as a
herapeutic option for patients with CLL.
Dreger et al [16] showed survival advantage of
uto-HCT compared to standard chemotherapy for
LL in a matched cohort study. In that analysis, 66
atients treated with auto-HCT after TBI: 12-14.4
y and CY (120 mg/kg) were matched against 291
atients treated with conventional chemotherapy. The
atching of 4 variables (age, Binet’s stage, IgVH mu-
ational status, and lymphocyte count) resulted in 44
ully matched pairs. The groups were also balanced
or expression of surface CD38 and adverse cytoge-
etic aberrations. Survival was superior in the auto-
CT group when calculated from either time of ini-
ial diagnosis (hazard ratio [HR] 0.39, P  .03) or
rom study entry (HR 0.32; P  .006). The beneﬁt of
uto-HCT remained statistically signiﬁcant when
nalysis was restricted to the unmutated IgVH status,
nd Cox regression analysis showed that auto-HCT
s an independent prognostic factor for favorable sur-
ival. These ﬁndings led us to conclude that auto-
04). (From Pasquini MC, He V, Perez W. Current use and outcome
lides, 2005. CIBMTR Newslett. 2006;12:5-10).548 to 20CT might offer a survival beneﬁt for patients with
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Stem Cell Transplantation in CLL 375oor-risk CLL. The question remains when is the
ptimal time to transplant these high-risk patients in
he course of their disease.
Clinicians are faced with decisions such as when to
onsider transplantation for CLL, what are the best
retransplant induction and conditioning regimens,
hether stem cell “purging” is beneﬁcial, what type of
urging (in vivo or ex vivo) is preferable, and how
hese patients should be followed after transplanta-
ion. Other important questions include treatment
ptions for those who do not achieve a CR, whether to
se MR as the endpoint posttransplantation, and pos-
remission molecular surveillance for those with un-
etectable minimal residual disease (MRD).
IMING OF AUTOLOGOUS HCT
LL Relapsing after Fludarabine
A phase I/II trial reported by Khouri et al [19], in
994, evaluated autologous or allogeneic marrow
ransplantation in patients with advanced CLL who
elapsed after ﬂudarabine therapy. Twenty-two pa-
ients received high-dose chemoradiation with
BI/CY followed by transplantation. Cyclosporine
nd methotrexate (5 to 10 mg/m2 on days 1, 3, 6, and
1) were used as prophylaxis for acute GVHD
aGVHD) in most allogeneic marrow recipients.
leven patients (50%) received autologous marrow
urged with anti-CD19 mAbs, and 11 patients re-
eived allogeneic or syngeneic marrow. After au-
ografting 10 (91%) patients achieved CR (4 nodular
R), and 1 (9%) a partial remission (PR). Six (55%) of
1 patients were alive in remission at 2 to 29 months
ollowing transplantation. The responses seen with
llo-BMT were CR: 7, nodular CR (nCR): 2, and PR:
. Ten (91%) of 11 were alive, with a median fol-
ow-up of 10 (range: 2-36) months. CLL responses
ere remarkable considering that most patients had
dvanced Rai stage III/IV. This and other studies are
ummarized in Table 1.
Other prospective studies have attempted auto-
CT in heavily pretreated CLL. In a trial by Sutton
t al [20], heavily pretreated relapsed/refractory CLL
atients (N  20) who had at least 2 prior regimens
ncluding a purine nucleoside analog underwent auto-
CT. Hematopoietic cell collection was attempted
ollowing treatment with ESHAP and 8 of 20 patients
ad sufﬁcient stem cells harvested for autografting. Six
75%) of 8 transplanted patients remained in CR at a
edian follow-up of 30 (range: 2-55) months after
CT. This study emphasizes the role of extensive
hemotherapy in depleting the stem cell pool, and
uggests considering HCT at an earlier stage of dis-
ase before cumulative hematologic toxicity results
rom prior therapies.A larger study by Gribben et al [17] reported a Ta In Kh Su
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M. A. Kharfan-Dabaja et al.376ong-term follow-up of 137 patients with relapsed
LL who received ex vivo purged autologous hema-
opoietic cells. Ninety- ﬁve percent had received prior
udarabine therapy. Ninety percent had unmutated
gVH. The conditioning regimen consisted of
BI/CY (TBI: 14 Gy and CY: 120 mg/kg) followed by
nfusion of autologous marrow “purged” with anti-
D20, anti-CD10, B5, and complement. TRM was
% at 100 days. The 6-year OS and progression-free
urvival (PFS) were 58% and 30%, respectively, with
o evidence of plateau in survival curves. The afore-
entioned 6-year OS appears better than would be
xpected in high-risk CLL, particularly when 90% of
atients had unmutated IgVH. In this study no differ-
nce in OS was observed when comparing autologous
ersus T cell depleted allo-HCT (58% versus 55%,
 .96). The apparent lack of a GVL effect might be
ttributed to T cell depletion of the allo-HCT. The
uthors also raise concern about the high incidence of
econdary myelodysplastic syndrome (MDS) and
cute myeloid leukemia (AML) of 12% at 8 years after
uto-HCT.
Trneny et al [21] evaluated 24 patients who had
een previously treated, progressed, or had at least 2
dverse prognostic factors. Patients received 4 cycles
f FCR followed by mobilization with ESHAP and
arvest of hematopoietic cells. Following FCR, the
bjective responses were CR: 6, nodular PR (nPR): 14,
nd PR: 4. Five (25%) of 20 evaluable patients at-
ained PCR negativity for CDRIII rearrangement.
wenty-three patients proceeded to stem cell mobili-
ation; 19 patients had a successful harvest, but only
7 proceeded with auto-HCT. The conditioning reg-
men consisted of BEAM followed by auto-HCT.
osttransplant responses were CR: 14 and PR: 1
2 patients with nodular PR had not been evaluated).
leven (92%) of 12 evaluable HCT patients achieved
CR negativity after transplant. At a median follow-up
f 26 months from treatment with FCR, there were 7
elapses/progressions and no deaths reported. Six of 7
elapses had poor prognostic features (unmutated
gVH gene), and 3 of them occurred in patients who
id not receive auto-HCT. This study concluded that
CR followed by BEAM is well tolerated and results
n high CR rates, including MRs. However, relapses
ccurred even after a PCR negative CR, most of them
ccurring in patients with IgVH unmutated gene.
utograft as Postinduction Consolidation
n “High-Risk” CLL
There are no randomized studies that compare
arly versus late auto-HCT for patients with high-risk
LL. A single-arm prospective study reported by
reger et al [22] evaluated 18 patients (median age: 49
ears) with high-risk CLL. The majority of patients,
6 of 18, had adverse prognostic factors and all had
olecular disease identiﬁed by PCR. Following treat- ient with Dexa-BEAM, 14 (77%) had blood stem
ells successfully harvested. Grafts were purged using
mmunomagnetic methods. Following conditioning
ith TBI/CY, 13 of 14 patients were reinfused with
urged stem cells. There were no transplant-related
eaths. One patient relapsed and 2 had persistent
olecular evidence of disease, but remained in clinical
R, at a median follow-up of 48 months. These ﬁnd-
ngs suggest a beneﬁcial role for early auto-HCT in
igh-risk CLL patients. Factors to consider when in-
erpreting these data are the selection of a relatively
ounger age population and the more favorable clin-
cal stages of the disease.
At the 2004 annual meeting of the American So-
iety of Hematology, the German Chronic Lympho-
ytic Leukemia Study Group presented a prospective
ulticenter trial evaluating the feasibility and efﬁcacy
f early auto-HCT in patients with high-risk CLL
23]. Unmutated IgVH rearrangement was present in
2%. Only 128 of 179 eligible patients were evaluable,
nd 86% of these patients were chemotherapy naïve at
tudy entry. Cytoreduction regimens (CHOP, ﬂu-
arabine alone, or ﬂudarabine and cyclophosphamide)
ere optional. Pretransplant documented responses
ere CR: 28% and PR: 64%. Patients underwent
eripheral blood stem cell (PBSC) mobilization using
he Dexa-BEAM regimen, followed by myeloablative
herapy with TBI/CY and then reinfusion of purged
tem cells. Ninety-eight (77%) of 128 patients pro-
eeded to auto-HCT. At 36 months of follow up,
edian progression free survival (PFS) analyzed on
ntent to treat was 59 months, and 54 months for
hose with unmutated IgVH. The OS at 4 years for all
28 patients was 84%. Nonhematologic toxicities
ere mainly from infections (18% pretransplant; 7%
osttransplant). Two of 6 fatal complications were
een in posttransplant setting, corresponding to a
RM of 5%. The study concluded that auto-HCT is
feasible and promising option for poor-risk CLL
atients. Table 1 summarizes the above ﬁndings.
utologous HCT as Postinduction Consolidative
herapy Regardless of Disease-Risk Status
A prospective study by the United Kingdom Med-
cal Research Council evaluated the role of auto-
CT, following induction therapy with single agent
udarabine, in 115 previously untreated CLL [24]. In
13 evaluable patients, responses after at least 3 cycles
f ﬂudarabine were CR: 19%, nodular PR: 33%, PR:
1%. Forty-four patients required further treatment
ith alternative treatments like alemtuzumab and
HOP. Twenty-nine patients failed to mobilize pe-
ipheral blood progenitor cells, and in 26 patients
obilization was not attempted because of inadequate
esponse to therapy. Sixty-ﬁve proceeded to autograft
fter TBI/CY: 49, BEAM: 11, BU/CY: 1, or not spec-
ﬁed: 4. After transplant 48 (74%) patients achieved or
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Stem Cell Transplantation in CLL 377aintained a CR, and 26 (63%) of 41 patients who
ere not in CR at the time of their HCT achieved CR
fter transplant. The 5-year disease-free survival
DFS) and OS from time of transplantation were 52%
nd 78%, respectively. Sixteen (80%) of 20 evaluable
atients achieved MR by PCR in the ﬁrst 6 months
ollowing transplantation. Secondary AML and MDS
ccurred in 5 (8%) of 65 patients (Table 1).
yelodysplastic Syndromes/Acute Myeloid
eukemias after Autologous HCT for CLL
Development of secondary MDS/AML after TBI-
ased preparative regimens is of concern in patients
ith CLL [17,24], as has been the case for other
ymphoid malignancies [25]. Gribben et al [17] re-
orted an MDS/AML incidence of 9% at a median of
6 (range: 11-87) months. Median time from auto-
CT to diagnosis of MDS/AML was 35 (range:
-138) months. At a longer follow-up of 8 years after
ransplantation, the incidence of MDS increased to
2%. Similarly, Milligan et al [24] showed an inci-
ence of MDS of 8%, developing only in patients who
eceived TBI-based regimens. A recent study by Jan-
unen et al [26] reported MDS in 2 (2.8%) of 72
atients at 10 to 19 months after auto-HCT. In this
tudy only 53% of the patients received a TBI-based
egimen, compared to 100% [17] and 75% [24] of the
atients in the previously described studies. Develop-
ent of MDS after auto-HCT within such a short
ime after transplantation is particularly worrying,
onsidering that CLL has a relatively long natural
istory.
Stem Cell “Purging.” Although auto-HCT re-
ults in a high CR rates, including MR, most patients
ventually relapse. Numerous purging procedures
ave been developed, including in vivo and ex vivo
urging using either immunomagnetic methods or
Abs or cytotoxic therapy to minimize the reinfusion
f leukemic cells.
Ex Vivo Purging. Rabinowe et al [18] evaluated 12
LL patients who underwent auto-HCT following ex
ivo purging of marrow stem cells using mAb (anti-
D10, anti-CD20, and B5) and complement. Ten
83.3%) of 12 patients achieved CR at a median follow
p of 11.7 months. This high degree of response
uggests that ex vivo purging is feasible, but longer
ollow-up is needed to draw more solid conclusions
bout efﬁcacy in preventing CLL relapse.
Dreger et al [27] analyzed the efﬁcacy of ex-vivo
urging of PBSC in 20 patients with poor-risk CLL
ndergoing uniform stem cell mobilization with
ouble B cell depletion of the harvested PBSC using
mmunomagnetic CD34 cell selection (Isolex300i
exell, Irvine, CA) followed by a negative step with
nti-CD19/20/23/37-labeled immunomagnetic beads.
uriﬁed PBSCs were reinfused following a myeloab-
ative regimen of TBI/CY. CLL cells were undetect- eble in 15 (60%) of 25 using ﬂow cytometry analysis.
apid and durable engraftment developed in all cases.
t a median follow-up of 20 months, 12 patients were
n CR and MR, 5 patients were in CR but with
vidence of molecular relapse, and 2 had recurrent
isease. These results do not exclude a positive role
or stem cell purging in lessening the incidence of
elapse; however, controlled studies are needed to
raw more solid conclusions. The development of the
umanized anti-CD52 mAb alemtuzumab has allowed
nvestigators to exploit its lympholytic activity with
he purposes of eradicating CLL before stem cell
ollection and hence is a reasonable in vivo purging
trategy before auto-HCT.
In Vivo Purging. Alemtuzumab has become an ef-
ective therapy for CLL because of its ability to
chieve CR in some patients and to purge CLL from
lood and BM [28]. As alemtuzumab is lympholytic, it
ay be effective for in vivo purging of blood and BM
rior to stem cell collection and HCT.
In a phase I trial, Tedeschi et al [29] utilized
lemtuzumab for in vivo purging in 14 patients ini-
ially treated with ﬂudarabine-containing regimens.
lemtuzumab was administered subcutaneously (10
g  3 weekly for 6 weeks). All patients in CR were
elected for transplantation. Nine patients showed
olyclonal rearrangement of the IgVH by PCR. There
ere no transplant related deaths. No CMV reactiva-
ion was seen following auto-HCT, even in 6 who had
eveloped CMV reactivation during prior alemtu-
umab administration. Posttransplant evaluation
howed that all patients remained in CR, and 13 had
Rs conﬁrmed by the presence of polyclonal IgVH
earrangement at a median follow up of 10 (range:
-30) months. The study shows that sequential ther-
py with in vivo purging followed by autograft is
easible. A recent update on 20 patients, presented at
he 2005 American Society of Hematology meeting
howed that all patients were in clinical CR by
CI-WG criteria, but only 65% of them were on MR
y PCR. In this update, alemtuzumab did not show an
ncreased incidence of late opportunistic infections
fter transplantation.
Another phase II study by Montillo et al [30]
valuated 34 patients receiving alemtuzumab to im-
rove responses, and for in vivo purging before PBSC
arvest. Alemtuzumab was administered as previously
escribed [29]. PBSC were mobilized using cytosine
rabinoside and granulocyte-colony stimulating factor
G-CSF). CR rates improved from 35% (after induc-
ion therapy) to 79% following alemtuzumab, includ-
ng a 56% MRD negativity by PCR. Cytomegalovirus
CMV) reactivation occurred in 18 patients, all of
hom were successfully treated with ganciclovir. He-
atopoietic cell collection was successful in 24 of 26
atients, but only 18 proceeded with auto-HCT. Sev-
nteen (94%) patients who underwent autografts were
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M. A. Kharfan-Dabaja et al.378n CR at a median follow up of 25.5 months. Patients
ho were not autografted showed progression of dis-
ase after a median of 7 months. Achieving MRs with
gents such as alemtuzumab represents a signiﬁcant
chievement and may provide further beneﬁcial long-
erm beneﬁt in CLL therapy.
Unfortunately, there is no standardized approach
or hematopoietic cell purging and measuring of MRs;
nd there are no randomized studies evaluating the
mpact of purging (in vivo or ex vivo) on outcome.
ell loss associated with marrow purging could be
voided by utilizing blood stem cells as source; how-
ver, the efﬁcacy of PBSC purging is not well docu-
ented either.
ignificance of MRD Kinetics Postautograft
Ritgen et al [31] showed that MRD kinetics after
uto-HCT for CLL correlate with IgVH mutational
tatus and predicts posttransplant outcome. In this
tudy, 476 blood samples from 46 patients were ana-
yzed by allele-speciﬁc oligonucleotide RQ-PCR. In
45 cases, BM samples obtained on the same occasion
ere analyzed at the same time. Blood and BM
howed highly signiﬁcant correlating MRD values
P .0001), with a tendency for better MRD and higher
ensitivity in BM. Myeloablative treatment with HCT
esulted in a strong reduction of the CLL “leukemic
oad” with no signiﬁcant difference between patients
ith mutated and unmutated IgVH. MRD levels had
o prognostic impact during the ﬁrst 6 months after
CT. Stable MRD kinetics between 6 and 12 months
fter HCT were strongly predictive for a favorable
utcome (4-year progression-free survival 100% ver-
us 37% for those patients who had increasing MRD
evels). However, increasing MRD levels early post-
ransplant strongly correlated with the unmutated
gVH. These ﬁndings suggest that myeloablative
CT can lead to substantial reduction of tumor load
n patients with CLL in remission. The investigators
uggest that inferior posttransplant outcome for pa-
ients with unmutated IgVH likely results from faster
egrowth of the leukemic clone rather than less effec-
ive reduction of MRD immediately after HCT. Al-
hough it is possible that patients with MRD-negative
inetics have intrinsically less aggressive disease,
chieving negative MRD status is a reasonable treat-
ent goal. One may argue that patients who do not
chieve MRD negativity or show MR/progression at 6
onths posttransplant may beneﬁt from additional
herapeutic interventions such as maintenance therapy
r posttransplant tumor vaccine strategies.
Recently, Moreno et al [32] analyzed MRD using
different methods. Samples were taken from 40
atients who have undergone HCT (autologous or
llogeneic). Several conclusions could be derived from
his study: (a) quantitative methods such as quantita- aive PCR and ﬂow cytometry have a very good corre-
ation among them, and are accurate for MRD detec-
ion, (b) detection of MRD on patients who undergo
utologous HCT was predictive of clinical relapse,
nd (c) patients having detectable MRD before 6
onths posttransplant were identiﬁed as “high risk”
or relapse. Interestingly, MRD detection did not have
n impact on allograft outcome in CLL. These ﬁnd-
ngs support the use of quantitative methods for MRD
etection in the assessment of response in CLL.
hether these observations will eventually translate
nto survival advantage to patients remain to be seen.
LLOGENEIC HEMATOPOIETIC CELL
RANSPLANTATION IN CLL
tandard Myeloablative Conditioning
Therapeutic beneﬁts of allo-HCT include infu-
ion of tumor-free hematopoietic cells from a healthy
onor and its ability to induce a GVL effect. Allo-
CT is, however, associated with high morbidity and
RM. Patients with CLL are older than patients un-
ergoing allo-HCT for other indications, hence con-
ributing to the higher morbidity rate. A database
egistry study of 54 patients (IBMTR and EBMT)
ith a median age of 41 years showed that allo-HCT
s feasible with a resulting TRM of 46%, hematologic
emission of 70%, and a 3-year probability of survival
f 46% [33]. In this study most patients received
BI/CY followed by infusion of marrow from HLA-
dentical siblings. An updated follow up showed that
he 10-year probability of survival and leukemia-free
urvival, for the entire initial group of 54 patients,
ere 41.2% and 36.6%, respectively. These ﬁndings
onﬁrm that CLL can be cured by conventional allo-
ibling BMT [34]. Another analysis from EBMT reg-
stry data showed a TRM of 50% and a 3-year OS
robability of 45% demonstrating a plateau effect as
ell [35].
Doney et al [36] reported the outcome of 25 pa-
ients (median age: 47 years) with CLL who received
ibling-donor HCT (HLA-identical siblings: 21; syn-
eneic: 3; HLA-mismatched sibling: 1). The 2 major
reparative regimens included BU/CY (busulfan total
ose: 14 mg/kg orally, cyclophosphamide total dose:
50 mg/kg IV) or TBI/CY (cyclophophamide: 120
g/kg, TBI: 10-16 Gy). TRM at 100 days was 57%
or patients conditioned with BU/CY and 17% for
hose receiving TBI-based regimens. Reasons for such
ncreased mortality with BU/CY may include: (a) use
f oral as opposed to i.v. busulfan, (b) no pharmaco-
inetics targeting busulfan was implemented, (c) high
oses of cyclophosphamide (150 mg/kg) was used.
eno-occlusive disease (VOD) of the liver was seen in
1 patients and renal failure in 6. An actuarial survival
t 5 years for the entire group was 32%. These and
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Stem Cell Transplantation in CLL 379ther studies are summarized in Table 2 [33,34,
7-39].
tandard Myeloablation Allogeneic HCT Using
nrelated Donors
Hematopoietic cell transplantation from unrelated
onors (URD) has been used for a variety of hemato-
ogic malignancies including CLL. Pavletic et al [39]
valuated 38 CLL patients, with median age of 45
ears, who received transplantation from URD BM
ransplantation following TBI-based (92%) myeloab-
ative regimen. Fifty-ﬁve percent were chemorefrac-
ory and 89% had received prior ﬂudarabine-contain-
ng regimens. Posttransplant immunosuppresion
rophylaxis consisted mostly of methotrexate and cy-
losporine (61%). Ten of 38 donors were HLA mis-
atched. Overall posttransplant responses were 75%
CR: 58%, PR: 17%). Five-year OS, failure-free sur-
ival (FFS), disease-progression rate, and TRM were
3%, 30%, 32%, and 38%, respectively. Seven (18%)
f 38 patients had graft failure (primary graft failure:
, secondary graft failure: 3). All 3 patients with sec-
ndary graft failure were HLA mismatched using old
yping technology, but only 1 of 4 with primary graft
ailure was HLA mismatched. This study demon-
trates that lasting remissions are achievable following
RD transplantation; however, high TRM, especially
or HLA mismatched donors suggest that better im-
unosuppressive regimens may be required to facili-
ate durable engraftments and prevent GVHD.
A study by Toze et al [40] evaluated outcome of 30
atients with CLL who received myeloablative allo-
CT using sibling donors (N  20) or URD (N 
0) at 2 transplant centers in Canada. The median
nterval from diagnosis to transplantation was 4.8 (0.3-
3) years, median number of prior therapies was 3,
nd median age 48 years. Preparative regimens in-
luded TBI-based regimens in 15 (50%) patients.
ourteen (47%) of 30 patients were alive at a median
ollow-up of 4.3 (2.4-10.5) years. Actuarial OS at 5
ears is 39% (OS: 48% for related-donor and 20% for
RD). Cumulative incidence of TRM and relapse is
7% and 19%, respectively.
Despite low relapse rates, survival after allo-HCT
n CLL and especially URD is relatively low predom-
nantly because of treatment-related death in patients
ith relatively advanced age, poor-risk or advanced
LL, and increased number of prior chemotherapies.
evelopment of reduced-intensity conditioning (RIC)
egimens has improved the tolerability of allo-HCT
hile reasonably preserving its GVL effect.
IC Regimens
Allo-HCT is the only treatment modality with
otential for inducing long-term DFS in CLL. How-
ver, OS at 3 to 4 years following standard myeloab- iative allo-HCT approach is reported to be only in the
ange of 45%-60% because of toxicity from the reg-
men and subsequent GVHD. This prompted evalu-
tion of less intense regimens that would preserve
rgan integrity and promote DFS.
In a population-matched analysis, Dreger et al
41] retrospectively compared 73 cases of CLL re-
eiving RIC (ﬂudarabine/cyclophosphamide: 21;
udarabine/melphalan: 17; ﬂudarabine/busulfan: 13;
udarabine/TBI: 10; TBI: 7; other: 5) to 82 cases who
nderwent standard myeloablative conditioning (cy-
lophosphamide/TBI: 69; melphalan/TBI: 4; busul-
an/cyclophosphamide: 4; other: 5) during the same
ime period. An unadjusted comparison of RICs and
tandard myeloablative conditionings, with median
ollow-up of 22 and 29 months respectively, did not
eveal signiﬁcant differences in OS, event-free survival
EFS), or TRM among the groups. There were fewer
elapses in the standard myeloablative group (11%
ersus 28%, P  .008). After adjustment for age,
ender, donor/cell source, and disease-remission sta-
us, a signiﬁcant reduction in TRM was observed in
he RIC population (HR: 0.4; 95% conﬁdence inter-
al: 0.18-0.9; P  .003). The favorable inﬂuence of
llogeneic RIC regimens on TRM, and the possible
nfavorable effects on risk of relapse requires conﬁr-
ation in prospectively randomized studies. It is im-
ortant to note that comparison of myeloablative and
IC regimens is complicated by fundamental differ-
nces in patient’s characteristics receiving each mo-
ality. RIC are generally biased to older patients with
linical comorbidities and less than optimal perfor-
ance status, making direct comparison inappropri-
te.
Another study by Dreger et al [42] evaluated 77
atients with CLL who received allogeneic-RIC
CT at 29 centers in Europe. The median age was 54
range: 30-66) years and the median number of prior
hemotherapy regimes was 3 (range: 0-8). Donors
onsisted of HLA-identical siblings in 81% of the
ases. Conditioning regimens were designated as
intensive” or “moderate.” Regimens were deﬁned as
ntensive if busulfan doses of 8 mg/kg, or melphalan
oses of110 mg/m2 were used. Moderate condition-
ng regimens (mainly low-dose TBI- or ﬂudarabine-
ased) were administered to 56% of patients. In vivo
cell depletion with antithymocyte globulin (ATG)
r alemtuzumab was administered in 40%. Prelimi-
ary multivariate analysis identiﬁed less than PR at
ime of transplant (HR 3.5; P  .01) and alternative
onors (HR: 3.1; P  .02) as risk factors for relapse.
ore than 2 prior treatment regimens (HR: 5.4; P 
.03), 2 Gy TBI-based regimens (HR: 2.5; P  .05)
nd alternative donors (HR: 2.3; P  .08) were risk
actors for adverse survival outcome. Prospective clin-
cal trials are needed to show whether RIC can im-
Table 2. Selected Studies of Allogeneic Hematopoietic Cell Transplantation in Patients with CLL
Study [Ref] Design N
Age
(median)
Conditioning
Regimen
GVHD
Prophylaxis
Stem Cell
Source TRM DFS/EFS OS
Standard myeloablative regimens
Michallet, et al.
IBMTR/EBMT [33,34]
Registry data 54 41 TBI/CY: 51
BU/CY: 3
MTXCSA (65%) Sibling: 100%
BM: 100%
unmanipulated
46% 36.6%
10-year LFS
46% at 3 years
41.2% at 10 years
Esteve et al.
International Project
[37]
Registry data 46 43 — — Sibling BM: 59%
T cell depleted: 31%
31% 45%
5-year EFS
56%
At 5 years
Doney et al. [36] Prospective single
arm
25 47 TBI/CY: 17
BU/CY: 7
Other: 1
MTXCSA (60%) Sibling BM: 88%
PBSC: 12%
48% — 32% at 5 years
actuarial
Pavletic et al. [38] Prospective single
arm
23 46 TBI/CY/VP16: 16
TBI/CY: 6
Other: 1
MTXCSA Sibling: 87%
URD: 13%
30% 65%
5 year-EFS
62%
At 5 years
Pavletic et al. IBMTR/
NMDP [39]
Registry data 38 45 TBI/CY: 29
Other TBI based: 6
CYother: 3
MTXCSA (61%)
MTXtacrolimus (21%)
URD: 100% 38% 30%
5 year-FFS
33%
At 5 years
Toze et al. [40] Prospective 30 48 TBI/CY: 15
BU/CY: 15
MTXCSA (93%) URD BM: 33%
Sibling BM: 67%
47% 39%
At 5 years
39%
At 5 years
Moreno et al. [48] Prospective NRC 23 49 TBI/CY: 15
FLU/MEL: 6
BU/CY: 1
FLU/TBI: 1
— — 17% 71% at
5 years
—
Reduced-intensity/nonmyeloablative conditioning regimens
Dreger et al. EBMT
[41]
Registry data 73 53 TBI 2Gy: 7
TBI/FLU: 10
FLU/BU: 13
FLU/MEL: 17
FLU/CY: 21
Others: 5
MTXCSA in majority of
cases
Sibling: 79%
URD: 21%
PBSC: 92%
19%
At 2 years
58%
2 year-EFS
70%
At 2 years
Scheteling et al. [43] Prospective 30 50 FLU/BU/ATG: 30 CSA: 23%
MTXCSA: 37%
MMFCSA: 40%
Sibling: 50%
URD: 50%
15%
At 2 yrs
67%
2 years PFS
72%
At 2 years
Sorror et al. [45] Prospective 64 56 TBI 2 Gy: 11
TBI/FLU: 53
MMFCSA Sibling PBSC: 44%
URD PBSC: 20%
22%
At 2 years
52%
2 years DFS
60%
At 2 years
Brown et al. [46] Prospective 46 53 FLU/BU: 46 MTXtacrolimus
simlimus (48%)
CSAprednisone (28%)
MTXtacrolimus (17%)
CSACD34 selection (7%)
URD: 67%
Sibling: 33%
PBSC: 98%
17%
At 2 years
34%
2 years PFS
54%
At 2 years
Caballero et al. [49] Prospective 30 46 FLU/MEL: 19
FLU/MEL/Alemtuzumab: 1
FLU/BU/ATG: 5
FLU/TBI/ATG: 5
MTXCSA: 93%
CSA: 7%
Sibling: 100%
PBSC: 100%
20% 72%
6 years-EFS
70%
At 6 years
TBI/CY indicates total body irradiation and cyclophosphamide; BU/CY, busulfan and cyclophosphamide; FLU/MEL, ﬂudarabine and melphalan; TBI/CY/VP16, total body irradiation, cyclophos-
phamide and etoposide; FLU/TBI, ﬂudarabine and total body irradiation; MTX, methotrexate; CSA, cyclosporine; MMF, mycophenolate mofetil; LFS, leukemia-free survival; EFS, event-free
survival; FFS, failure-free survival; PFS, progression-free survival; DFS, disease-free survival; OS, overall survival; URD, unrelated donor; NRC, nonrandomized comparison; PBSC, peripheral blood
stem cells; TRM, transplant-related mortality; CLL, chronic lymphocyte leukemia.
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Stem Cell Transplantation in CLL 381rove the outcome of allo-HCT for CLL by reducing
RM, whereas hopefully preserving the GVL.
Schetelig et al [43] evaluated a regimen of ATG in
ombination with ﬂudarabine and busulfan in 30 pa-
ients (sibling: 13; non-HLA identical family mem-
ers: 2; URD: 15) with advanced CLL. Despite
VHD prophylaxis with ATG followed by postgraft-
ng with cyclosporine and methotrexate (or mycophe-
olate mofetil) the incidence of aGVHD grade II-IV
nd extensive chronic GVHD (cGVHD) were higher
n URD compared to HLA-identical sibling trans-
lants (87% versus 27%, P  .003, and 31% versus
3%, respectively). Twenty-three (77%) of 30 pa-
ients were alive after a median follow-up of 2 years,
nd the overall relative risk (ORR) was 93% (CR:
0%, PR: 53%). The probability of 2-year OS, PFS,
nd TRM were 72%, 65%, and 15%, respectively.
atal opportunistic infections were reported in 4
13%) of patients. These results demonstrate that ad-
ition of ATG does not prevent aGVHD and may
mpair the GVL effect. A randomized trial of ATG,
owever, has shown to be able to decrease incidence
f cGVHD [44]. In the absence of objective and es-
ablished criteria to quantitate the “ablative intensity”
f various chemotherapy or chemo-radiotherapy com-
inations, many preparative regimens are included
nder the rubric of RIC or nonmyeloablative, and all
ay not be equivalent.
Sorror et al [45] evaluated a nonmyeloablative
egimen of TBI (2 Gy) alone (N  11) or TBI plus
udarabine (N  53) in patients, median age of 56
ears, with advanced CLL. Graft rejections were ob-
erved in 3 patients. The 2-year TRM was 22%. The
RR among 61 patients with measurable disease was
7% (CR: 50%). The 2-year rate of OS and DFS were
0% and 52%, respectively. URD allo-HCT resulted
n higher CR (78% versus 42%, P  .005) and lower
-year relapse rates (5% versus 34%, HR: 0. 3, P 
08) likely mediated by a more effective GVL effect.
his nonmyeloablative FLU/TBI low-dose regimen
s well tolerated, but a and c GVHD remain a concern.
A study recently published by Brown et al [46]
valuated a nonmyeloablative combination of ﬂudara-
ine and low-dose i.v. busulfan without ATG in 46
atients with advanced CLL. Median time from diag-
osis to transplantation was 6.5 years, and the median
umber of previous therapies were 5, including prior
udarabine (98%) and auto-HCT (22%). GVHD
rophylaxis was based on calcineurin inhibitors in
00% and T cell depletion in 7% of patients, respec-
ively. The incidence of grade II-IV acute and ex-
ensive cGVHD were 34% and 38%, respectively.
he 100-day TRM was 2% and the 2-year TRM
as 17%. ORR was 59% (CR: 35%, PR: 24%). The
-year PFS and OS were 34% and 54%, respectively.
he authors conclude that increasing number of priorherapies contributed to the relatively decreased PFSnd OS, emphasizing to consider intervening with
llo-HCT at an earlier stage of the disease. In this
tudy, adverse cytogenetic features were associated
ith a reduced PFS in univariate, but not in multivar-
ate analysis. The ability of allo-HCT to overcome
dverse prognostic factors such as chromosomal ab-
ormalities 11q- and 17p- and expression of unmu-
ated IgVH has been proposed in various clinical trials.
llogeneic HCT and Unmutated IgVH Status
Ritgen et al [47] found that allo-HCT is effective
n high-risk CLL with unmutated IgVH status. Nine
atients with unmutated IgVH received allo-HCT fol-
owing nonmyeloablative conditioning with ﬂudara-
ine and cyclophosphamide, and 26 patients an auto-
CT following TBI/CY. The kinetics of MRD was
easured by quantitative allele-IgVH PCR [39]. MRD
ecame undetectable beyond day 100 in 7 (78%) of
after allogeneic HCT and development of cGVHD
r after donor lymphocyte infusions, and those 7 pa-
ients remained in CR and MR at a median follow-up
f 25 (range: 14-37) months. On the other hand, PCR
egativity was achieved in only 6 (23%) of 26 patients
fter auto-HCT for unmutated IgVH, and was not
urable. These ﬁndings demonstrate that elimination
f MRD in CLL postallogeneic HCT is dependent to
great extent on a bona ﬁde GVL effect rather than
he sole cytotoxic effect of the conditioning regimen
er se.
A study by Moreno et al [48] evaluated 50 patients
ith poor-risk CLL (deﬁned as advanced clinical
tage, diffuse BM inﬁltration, short doubling-time,
assive or progressive lymphadenopathy, or poor-risk
ytogenetics) who underwent auto- (N  27) or allo-
CT (N  23) and had available data on IgVH se-
uences. Thirty-four (68%) patients (allogeneic: 14;
utologous: 20) had unmutated IgVH genes. There
ere no signiﬁcant differences among the groups in
atient age, sex, and time from diagnosis to transplant.
mong all patients, the risk of relapse at 5 years was
igher following auto-HCT (61%; 95% CI: 44%-
4%) than after allo-HCT (12%; 95% CI: 3%-44%;
 .05). Also, EFS at 5 years was superior for allo-
CT patients (71% versus 17%, P  .0002). In pa-
ients with unmutated IgVH, the 5-year incidence of
rogression was 66% following auto-HCT (95% CI:
7%-93%) compared with 17% (95% CI: 5%-60%,
 .01) after allo-HCT, with a median time to
rogression of 28 months. However, no difference in
he OS was observed with median survivals of 6 and 4
ears after allo-HCT and auto-HCT, respectively
P  .33). These ﬁndings support the concept that
VL effect can overcome the risk of disease progres-
ion associated with unmutated IgVH gene in patients
ith CLL.Caballero et al [49] also demonstrated that RIC
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M. A. Kharfan-Dabaja et al.382llo-HCT is capable of overcoming the unfavorable
rognosis associated with unmutated status of IgVH
nd chromosomal abnormalities like 17p- and 11q-.
hirty patients with CLL with a median age of 53
ears and a median of 3 previous lines of therapy,
ncluding 37% refractory to ﬂudarabine, received
LA matched-sibling RIC HCT at 1 of 8 centers in
pain. RIC are described in Table 2. Fourteen (60%)
f the 23 patients had an unmutated IgVH status; 8
32%) of 25 patients had 11q- with 4 of 8 also dis-
laying unmutated IgVH; 6 (24 %) had 17p aberration
5 were also unmutated for IgVH ). All patients re-
eived G-CSF mobilized PBSC from matched-related
onors. Twenty-ﬁve (83.3%) patients in this study
ad active disease at the time of transplant, includ-
ng 6 with refractory/progressive disease. Twenty-
ne (78%) of 27 evaluable patients achieved CR by
ay 100. At a median follow-up of 47.3 months, 22
atients were alive and in remission. The 5-year ac-
uarial DFS, EFS, and OS were 93%, 70%, and 72%,
espectively. These studies conﬁrm the efﬁcacy of
llogeneic RIC transplantation in high-risk CLL even
n the presence of adverse cytogenetic abnormalities
ike 17p- and 11q-.
Cell Depletion Strategies in Allogeneic
CT for CLL
Depletion of T cells represents an effective mean
f reducing the incidence and severity of a or
GVHD, albeit at the increased risk of graft rejection,
pportunistic infections, or disease relapse. Several
ethods for depleting T cells have been developed
nd implemented over the years.
In Vivo T Cell Depletion. Delgado et al [50] evalu-
ted an in vivo T cell depletion strategy with alemtu-
umab in combination with ﬂudarabine and melpha-
an in 41 consecutive patients with CLL undergoing
llo-HCT. Donors were HLA-matched siblings (N 
4) or URD (N  17). Four (23.5%) of 17 URD were
LA mismatched. The regimen was alemtuzumab 20
g/day on days8 to4, ﬂudarabine 30 mg/m2 daily
n days 7 to 3, and melphalan 140 mg/m2 on day
2. GVHD prophylaxis consisted of cyclosporine ta-
ered 3 months after transplantation in the absence of
VHD. A and c GVHD were observed in 41% and
3% of the patients, respectively. TRM was 26%, and
esulted primarily from severe opportunistic bacterial,
iral, and fungal infections. The 2-year OS was 51%.
hese ﬁndings demonstrate that alemtuzumab-con-
aining regimens can reduce the incidence of GVHD,
lbeit at the expense of increased TRM from oppor-
unistic infections and relapse from malignancy.
Ex Vivo T Cell Depletion. Waldmann et al [51]
valuated the monoclonal rat antihuman lymphocyte
ntibody Campath 1G for ex vivo depletion of T-
ymphocytes from human HLA-matched BM sibling-
llografts prior to transplantation in 11 high-risk pa- cients with various hematologic malignancies. No
igns of GVHD developed in any of the patients, who
ere observed for a maximum period of 12 months
espite the fact that no anti-GVHD prophylaxis was
dministered. However, late graft failure was observed
n 18% of patients.
Gribben et al [17] evaluated the outcome of 25
LL patients undergoing matched-sibling allo-HCT
sing T cell-depleted marrow with anti CD6 and
omplement. TRM was 24%; the 6-year OS and PFS
ere 55% and 24%, respectively. Disease progression
as observed in 68%.
These ﬁndings are consistent with the concept
hat T cell depletion results in higher relapse rates,
ence signiﬁcantly reducing the curative potential of
llografting in CLL. These ﬁndings strongly suggest
hat T cells are important mediators of GVL in CLL,
nd DLI may be effective to control CLL after T-
epleted HCT.
ow Convincing Is the Evidence for
Graft-versus-CLL Effect
Animal models of allo-HCT have elucidated that
enetic disparity between donors and recipients are
irectly responsible for a GVL effect that contributes
o tumor eradication. A variety of immune cells have
een implicated in the GVL effect including T cells,
K cells, and B cells. T cells are capable of recogniz-
ng minor histocompatibility- or leukemia-associated
ntigens [52,53]. However, as these minor antigens
re also expressed on normal host cells, their recog-
ition could also result in the development of a less
esirable GVHD effect. Contrary to autologous,
yngeneic or T cell-depleted HCT, relatively fewer
elapses occur after allogeneic transplantation in
atients with CLL (myeloablative, RIC, nonmyeloa-
lative) and the incidence of relapse decreases over
ime; in addition, survival curves appear to reach a
lateau over time (Figure 1), suggesting that a GVL
henomenon is responsible for the long-term control
f CLL after T cell-replete allo-HCT [33,34,40,41].
he adoptive immunotherapy effect mediated via
VL can overcome adverse prognostic features in
LL patients including poor cytogenetics (17p-, 11q-)
nd the presence of unmutated IgVH [47-49].
ONCLUSION
A better understanding of novel prognostic mark-
rs and its implications may further facilitate the de-
igning of more rational clinical trials aimed at eval-
ating whether more aggressive therapy at an earlier
tage of disease could improve survival in high-risk
LL. Studies investigating auto-HCT have shown
hat it is a safe procedure associated with low TRM; it
an also deliver impressive remissions, clinical and
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Stem Cell Transplantation in CLL 383olecular, in a signiﬁcant number of patients. None-
heless, these remissions are not long lasting, and
elapses are anticipated. Unfortunately, auto-HCT
acks a plateau effect in survival curves (Figure 1). Also,
ot achieving MRD negativity or loss of MRs is highly
redictive of disease relapse. Contamination of rein-
used hematopoietic cells is also a concern, and further
esearch is needed to reﬁne stem cell purging strate-
ies (in vivo or ex vivo) to make this approach more
ffective. Other unsolved questions include optimal
ime to transplant, best conditioning regimens, and
eveloping universally applicable and reproducible
osttransplant MRD surveillance strategies. Patients
chieving MRD negativity or MRs may beneﬁt from
loser surveillance that will allow retreatment at an
arlier stage of a relapse with low tumor burden,
lthough it is not yet proved that earlier retreatment
ill improve survival. On the other hand, posttrans-
lant approaches such as maintenance therapy or vac-
ination strategies may be considered, within the con-
ext of clinical trials, in those patients in CR, but not
n MRs after autografts.
Allogeneic HCT has the ability to cure patients
ith CLL at the expense of an increased risk of mor-
idity and mortality. Standard myeloablative allo-
CT is associated with high levels of toxicity and risk
f death. On the other hand, RIC regimens have
educed TRM while reasonably preserving the bene-
cial GVL effect. The best timing to recommend RIC
llogeneic transplants remains to be determined even
n patients with high-risk features.
HCT, autologous or allogeneic (after myeloabla-
ion or RIC), in high-risk CLL represent promising
reatment options that should be considered preferen-
ially in the context of well-designed clinical trials.
hysicians need to educate patients about balancing
isks and beneﬁts associated with HCT or other treat-
ent options prior to selection of therapy.
REATMENT RECOMMENDATIONS
elapsed CLL
Patients of any age with relapsed CLL after ﬂu-
arabine-based therapy or with high-risk prognostic
eatures should be referred to transplant centers as
arly as possible to assess candidacy for transplant, and
f appropriate initiate the process of identifying a suit-
ble HLA-matched donor. Early referral would avoid
xcessive cumulative toxicities that may result from
ultiple lines of therapy. Patients with CLL are gen-
rally of advanced age with poor performance status
nd associated comorbidities; therefore, caution
hould be exerted when recommending standard my-
loablative regimens to these patients. Reducing the
ntensity of preparative regimens (RIC or nonmyeloa-
lative) has translated into lower treatment-associatedoxicities while preserving its curative potential, and is
reasonable treatment option for such patients once a
uitable HLA-matched donor is identiﬁed. In younger
atients with better performance status, able to toler-
te the morbidity from high doses of therapy, standard
yeloablative or RIC regimens are considered accept-
ble options. These interventions should be preferably
erformed within clinical trials whenever possible.
In cases where a suitable HLA-matched donor is
ot identiﬁed, auto-HCT could be considered. This
ntervention should be pursued as early as possible to
void multiple lines of therapy that may potentially
mpair the ability to harvest sufﬁcient hematopoietic
tem cells to perform the procedure.
reviously Untreated High-Risk CLL
In the absence of preliminary evidence from clin-
cal trials that evaluate autologous or allogeneic HCT
s ﬁrst-line treatment for high-risk CLL, these inter-
entions should be considered in the context of clin-
cal trials. Patients with P53-positive CLL are refrac-
ory to ﬂudarabine, and transplantation of such
atients appears logical but also should be performed
n the context of clinical trials.
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